Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New hope for patients with rare genetic diseases

23.08.2005


Because of the very high costs in developing drugs for rare genetic diseases, and the low return on investment, the pharmaceutical industry has rarely developed specific treatments for many of these diseases. But a new public-private partnership, called the European Rare Diseases Therapeutic Initiative (ERDITI), could provide an important new mechanism for developing new drugs.



In an article in this month’s open access international medical journal PLoS Medicine, Alain Fischer, Head of the Department of Pediatric Immunology at the Necker University Hospital, Paris, France, and colleagues describe how ERDITI (www.erditi.org) is bringing drug companies and academic researchers together to find new treatments for rare diseases.

"The thousands of compounds that have been developed by pharmaceutical companies for more common diseases but that were abandoned or failed to achieve registration for several reasons (such as biopharmaceutical properties, toxicity, lack of efficacy, or strategic reasons) represent a treasure worth exploiting," say the authors.


The idea behind ERDITI is that participating drug companies give these "abandoned" compounds to academic researchers who then investigate whether the compounds might be effective for treating rare diseases. Companies benefit from this relationship with academia in many ways, say the authors--for example, by demonstrating corporate social responsibility. The research on treatments for rare diseases may also lead to the discovery of drugs for the treatment of more common diseases, which could be highly profitable to industry.

The ERDITI partnership between industry and academia, say the authors, is governed by a charter of collaboration which includes "a standard agreement that describes the objectives of the research and defines the framework for the transfer and use of compounds. It also defines the rights and obligations of each party in terms of protection of information, intellectual property, and industrial property."

Paul Ocampo | EurekAlert!
Further information:
http://www.plos.org
http://www.plosmedicine.org

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>